Health Insurance Innovations, Inc. (HIIQ) Next Support Is Here

It has been reported that multiple insider activity took place at Health Insurance Innovations, Inc. (HIIQ). Director FICHTHORN JOHN acquired 93,742 shares for $183,608 in transaction occurred on 2019/03/20. After making this transaction, Director owns a direct stake of -19 shares, worth $4,379,051, as per the last closing price. On 2019/03/20 GABOS PAUL G, Director at HIIQ, purchased 8,000 shares at an average price of $29.91 per share. The new stake is valued at $1,737,926.

Director, AVERY PAUL E had invested in 3,000 shares for $25,889 through a trade on 2019/03/20. Following this activity, the insider holds -20 shares worth $617,453 as of recent close.

Innovator IBD 50 ETF revealed as top hedge fund owner in Health Insurance Innovations, Inc. (HIIQ) with a stake of over 305,474 HIIQ shares as of February 27, with a market value of approx. $11.37M as of today. The second largest holder, Vanguard Total Stock Market Index Fund, with 304098 shares which equates to $18.75M worth of the stock. At third is AMG Timessquare Small Cap Growth Fd, which stood pat with 294500 shares, a 4.52% position in Health Insurance Innovations, Inc., worth $18.16M. The insider holding in stood at 5.3% while institutions hold 0%.

Health Insurance Innovations, Inc. (NASDAQ:HIIQ) dropped -7.63% in recent trade and currently has a stock-market value of $401.87M. The shares finished at $23.85, after trading as low as $23.37 earlier in the session. It hit an intraday high Friday at $26.1412. Trading activity significantly improved as the volume at ready counter increased to 1,767,519 shares versus 1,050,870 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 940,314 shares. The stock is now 10.16% above against its bear-market low of $21.65 on May 03, 2018. It has retreated -164.7% since it’s 52-week high of $63.13 reached in October. Now the market price is down -15.12% on the year and down -10.77% YTD.

HIIQ stock’s 50 day simple moving average (SMA 50) price is $34.64 and its 200-day simple moving average (SMA 200) price is $39.58. The company’s stock currently has a total float of 13.25M shares. Its weekly volatility is hovering around 6.64% and felt 7.36% volatility in price over a month. On the upside, the share price will test short term resistance at around $25.54. On a downside, the stock is likely to find some support, which begins at $22.77. The failure to get near-term support could push it to $21.68.

It had seen a positive analyst call from B. Riley FBR, which upgraded the stock from Neutral to Buy on March 18. Analysts at B. Riley FBR, shed their positive views on February 27 by lowering it fromBuy to Neutral. Brokerage firm Lake Street, looks cautious as they stick to prior recommendation of Buy, in a call on October 31. However, they did change the target price from $51 to $75. First Analysis Sec analysts came out with bullish views on October 29 when the call was made. They think the stock is now Strong Buy compared to to their prior call for Outperform.

When looking at valuations, Health Insurance Innovations, Inc. (HIIQ) has a pricey P/E of 24.39x as compared to industry average of 13.44x. Moreover, it trades for 6.06 times the next 12 months of expected earnings. Also, it is trading at rather expensive levels at just over 2.74x price/book and 1.14x price/sales. Compared to others, Health Insurance Innovations, Inc. is in a different league with regards to profitability, having net margins of 3.7%. To put some perspective around this, the industry’s average net margin is 6.49%. HIIQ’s ROE is 13.3%, which is also considerably better than the industry’s ROE of 5.31%.

Shares of HIIQ have dropped -32.1% since the company’s most recent earnings report. Over the past 12 fiscal quarters, Health Insurance Innovations, Inc. (NASDAQ:HIIQ) has topped consensus earnings estimates in 8 quarters (66%), missed earnings in 4 quarters (33%), whereas at 0 occasion EPS met analyst expectations. HIIQ last reported earnings that exceeded expectations. The company raked in $0.98 per share, -96.5% change on the same period last year. That was better than consensus for $0.77. Revenue for the recent quarter stood at $131.92 million, up 90% on last year and above the $83.12 million predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $82.65 million to $106.4 million, which should be compared with $0 generated last year. EPS is seen in a range of $0.53 to $0.77, against the $0.74 reported a year ago.